Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A

Immune responses to coagulation factors VIII (FVIII) and IX (FIX) represent primary obstacles to hemophilia treatment. Previously, we showed that hematopoietic stem cell (HSC) retroviral gene therapy induces immune nonresponsiveness to FVIII in both naive and preimmunized murine hemophilia A setting...

Full description

Bibliographic Details
Main Authors:	Allison M Lytle, Harrison C Brown, Na Yoon Paik, Kristopher A Knight, J Fraser Wright, H Trent Spencer, Christopher B Doering
Format:	Article
Language:	English
Published:	Elsevier 2016-01-01
Series:	Molecular Therapy: Methods & Clinical Development
Online Access:	http://www.sciencedirect.com/science/article/pii/S2329050116301462

Similar Items

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
by: Harrison C Brown, et al.
Published: (2014-01-01)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
by: Sajjad Afraz, et al.
Published: (2022-11-01)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
by: Cansu Hemşinlioğlu, et al.
Published: (2023-06-01)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
by: Louise H Hooimeijer MD, et al.
Published: (2023-03-01)

Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A
by: Rou Xiao, et al.
Published: (2024-03-01)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity
by: Martin Rodriguez, et al.
Published: (2023-07-01)

The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia
by: Yingzi Zhen, et al.
Published: (2024-12-01)

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs
by: Janine Becker-Gotot, et al.
Published: (2022-11-01)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
by: Yuanhua Cai, et al.
Published: (2020-06-01)

A graph-based machine learning framework identifies critical properties of FVIII that lead to hemophilia A
by: Marcos V. Ferreira, et al.
Published: (2023-05-01)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
by: Di Ai, et al.
Published: (2022-11-01)

The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
by: Ilja Oomen, et al.
Published: (2024-02-01)

The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
by: Oomen, I, et al.
Published: (2024)

P1662: OPTIMIZED PROPHYLAXIS BASED ON INDIVIDUALIZED TARGET TROUGH FVIII LEVEL IN PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A
by: K. Huang, et al.
Published: (2022-06-01)

Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A
by: Chia-Yau Chang, et al.
Published: (2023-03-01)

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII
by: Ritu M. Ramamurthy, et al.
Published: (2022-12-01)

FVIII inhibitor surveillance in children with hemophilia A in Indonesia: a report from the Indonesian Pediatric Hematology-Oncology Working Group
by: Chozie, Novie Amelia, et al.
Published: (2022)

Hemophilia A subjects with an intron-22 gene inversion mutation show CD4+ T-effector responses to multiple epitopes in FVIII
by: Devi Gunasekera, et al.
Published: (2023-03-01)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
by: Jaquelyn T. Zoine, et al.
Published: (2019-08-01)

QUANTITATIVE PHARMACOKINETIC MODEL TO CHARACTERIZE AND EXTRAPOLATE LONG-TERM FVIII ACTIVITY LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH VALACTOCOGENE ROXAPARVOVEC
by: L Loureiro, et al.
Published: (2023-10-01)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
by: Christian Lubich, et al.
Published: (2022-10-01)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
by: Laura H. Bukkems, et al.
Published: (2023-05-01)

Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A: subanalysis of the randomized, phase 3 PROPEL study
by: Carmen Escuriola-Ettingshausen, et al.
Published: (2023-06-01)

In-Silico Characterization of von Willebrand Factor Bound to FVIII
by: Valentina Drago, et al.
Published: (2022-08-01)

Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation
by: Swystun LL, et al.
Published: (2023-03-01)

Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels
by: Brady Trevisan, et al.
Published: (2022-12-01)

The intersection of vector biology, gene therapy, and hemophilia
by: Leszek Lisowski, et al.
Published: (2021-08-01)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
by: Scott A. Becker, et al.
Published: (2023-06-01)

Combination of <i>CLEC4M</i> rs868875 G-Carriership and <i>ABO</i> O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients
by: Barbara Lunghi, et al.
Published: (2022-01-01)

In Vitro Modeling of the Influence of FVIII Activity and Heparin Induced Prolongation of APTT
by: Aida Mehmedagić, et al.
Published: (2008-08-01)

Elevated FVIII levels in hereditary hemorrhagic telangiectasia: Implications for clinical management
by: Ole Jakob Jørgensen, et al.
Published: (2024-02-01)

Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of <i>ITGA2B</i> Promoter-Driven <i>BDDF8</i> Gene in Hemophilia A
by: Junya Zhao, et al.
Published: (2022-01-01)

Treatment adherence in hemophilia
by: Thornburg CD, et al.
Published: (2017-09-01)

Thrombopoietin from hepatocytes promotes hematopoietic stem cell regeneration after myeloablation
by: Longfei Gao, et al.
Published: (2021-08-01)

Hepatocyte growth factor, a determinant of airspace homeostasis in the murine lung.
by: Carla Calvi, et al.
Published: (2013-01-01)

Stathmin 1 Induces Murine Hepatocyte Proliferation and Increased Liver Mass
by: Enpeng Zhao, et al.
Published: (2020-01-01)

Pontin is essential for murine hematopoietic stem cell survival.
by: Bereshchenko, O, et al.
Published: (2012)

Hemophilia /
by: 191745 Raabe, Michelle
Published: (2008)

Hemophilia
Published: (2009-03-01)

Ozone Exposure Controls Oxidative Stress and the Inflammatory Process of Hepatocytes in Murine Models
by: Silvania Mol Pelinsari, et al.
Published: (2024-02-01)